Prometheus Biosciences (formerly known as Precision IBD) is a biopharmaceutical company committed to the discovery, development, and commercialization of therapeutics and diagnostics for patients with gastroenterology and autoimmune diseases. Its clinical biobank with paired longitudinal medical records enables the identification of targets for the treatment of patients with biomarker-defined subclinical gastrointestinal (GI) phenotypes.